Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 9, 2014, Pages 1044-1055

  Ma, C ^a   Huang, V ^a   Fedorak, D K ^a   Kroeker, K I ^a   Dieleman, L A ^a   Halloran, B P ^a   Fedorak, R N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; METHOTREXATE; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; COHORT ANALYSIS; CROHN DISEASE; CYTOPENIA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HARVEY BRADSHAW INDEX; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; OUTPATIENT; PANCREATITIS; RETROSPECTIVE STUDY; SCORING SYSTEM; SECONDARY LOSS OF RESPONSE; DISEASE MANAGEMENT; DOSE RESPONSE; FOLLOW UP; MIDDLE AGED; TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; CROHN DISEASE; DISEASE MANAGEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84907963645     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12940     Document Type: Article

References (25)

1. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
2. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-9.
3. Swoger JM, Loftus EV Jr, Tremaine WJ, et al. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis 2010; 16: 1912-21.
4. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
5. Ma C, Huang V, Fedorak DK, et al. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study. [published online ahead of print 2014 Jun 16]. J Crohns Colitis 2014; doi: 10.1016/j. crohns.2014.05.007.
6. Billioud V, Sandborn WJ, Peyrin- Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011; 106: 674-84.
7. D'Haens GR, Panaccione R, Higgins PD, et al. The London position statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and colitis organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106: 199-212; quiz 213.
8. Ma C, Panaccione R, Heitman SJ, Devlin SM, Ghosh S, Kaplan GG. Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab. Aliment Pharmacol Ther 2009; 30: 977-86.
9. Oussalah A, Babouri A, Chevaux JB, et al. Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience. Aliment Pharmacol Ther 2009; 29: 416-23.
10. Swaminath A, Ullman T, Rosen M, Mayer L, Lichtiger S, Abreu MT. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naive patients. Aliment Pharmacol Ther 2009; 29: 273-8.
11. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 1: 514.
12. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-53.
13. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137: 1628-40.
14. Panaccione R, Loftus EV Jr, Binion D, et al. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. Can J Gastroenterol 2011; 25: 419-25.
15. Lofberg R, Louis EV, Reinisch W, et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE. Inflamm Bowel Dis 2012; 18: 1-9.
16. Ma C, Huang V, Fedorak DK, Kroeker KI, Dieleman LA, Fedorak RN. Su1396 Crohn's Disease Outpatients Treated With Adalimumab Have an Earlier Loss of Response and Requirement for Dose Intensification Compared to Infliximab. Gastroenterology;146: S- 457-8.
17. Sandborn WJ, Colombel JF, Schreiber S, et al. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 2011; 17: 141-51.
18. Ng SC, Plamondon S, Gupta A, et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas. Am J Gastroenterol 2009; 104: 2973-86.
19. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008; 28: 1122-6.
20. Baert F, Glorieus E, Reenaers C, et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients. J Crohns Colitis 2013; 7: 154-60.
21. Bultman E, de Haar C, van Liere-Baron A, et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther 2012; 35: 335-41.
22. Nichita C, Stelle M, Vavricka S, et al. Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease. Digestion 2010; 81: 78-85.
23. Sutharshan K, Gearry RB. Temporary adalimumab dose escalation is effective in Crohn's disease patients with secondary non-response. J Crohns Colitis 2013; 7: e277-8.
24. RoblinX, RinaudoM,DelTedesco E, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.AmJ Gastroenterol 2014; 109: 1250-56.
25. Imaeda H, Takahashi K, Fujimoto T, et al. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease. J Gastroenterol 2014; 49: 100-9.